Delphia Therapeutics
Reza Mazhari is a seasoned executive with extensive experience in the biopharmaceutical sector, currently serving as Chief Business Officer at Delphia Therapeutics since May 2025 and previously at TRIANA Biomedicines. From 2017 to June 2023, Reza led the Search and Evaluation team for North America at Novartis Institutes for BioMedical Research, focusing on oncology and other therapeutic areas, while also co-leading out-licensing efforts. Reza's earlier roles include Vice President positions in Translational Medicine and Drug Discovery at Rexahn Pharmaceuticals and Cerecor Inc., respectively, as well as significant contributions at Cardioxyl Pharmaceuticals and Artesian Therapeutics. Reza's academic background includes a B.S. and Ph.D. in Bioengineering from UC San Diego and a postdoctoral fellowship in Cardiovascular Medicine from The Johns Hopkins University School of Medicine.
This person is not in any teams
This person is not in any offices
Delphia Therapeutics
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.